Skip to main content

Cytometry

Rare Event Analysis

Overview of Rare Event Analysis

  • Definition: Rare event analysis is the process of identifying and quantifying cell populations that occur at very low frequencies in a sample.
  • Challenges:
    • Low Frequency: Target cells may be present at very low frequencies, making them difficult to detect
    • Background Noise: High background noise can obscure the signal from the target cells
    • Sample Volume: Limited sample volume may restrict the number of events that can be acquired
    • Specificity: Distinguishing rare events from background noise requires careful consideration of the specificity of the assay
  • Importance:
    • Disease Diagnosis: To detect early signs of disease or monitor treatment response
    • Therapeutic Monitoring: To monitor the effectiveness of therapies that target rare cell populations
    • Research: To study the biology of rare cell populations and their role in disease
  • Common Applications:
    • Circulating Tumor Cells (CTCs)
    • Measurable (Minimal) Residual Disease (MRD)
    • Circulating Endothelial Cells (CECs)

Circulating Tumor Cells (CTCs)

  • Definition: Cells that have shed from a primary tumor and are circulating in the bloodstream
  • Clinical Significance:
    • Prognosis: CTC counts can be used to predict the course of the disease
    • Therapeutic Monitoring: Changes in CTC counts can be used to monitor the response to treatment
    • Early Detection: CTC detection may allow for earlier detection of cancer recurrence
  • Methods for CTC Detection:
    • Enrichment:
      • Immunomagnetic Enrichment: Uses antibodies against cell surface markers to capture CTCs from the sample
      • Microfluidic Devices: Uses microfluidic devices to separate CTCs from other cells based on size or other properties
    • Detection:
      • Immunofluorescence Staining: Uses fluorescent antibodies to identify CTCs based on their expression of specific markers (e.g., epithelial cell adhesion molecule (EpCAM), cytokeratins)
      • Flow Cytometry: Uses flow cytometry to quantify the number of CTCs in the sample
  • Markers Used for CTC Detection:
    • Epithelial Markers:
      • EpCAM: A cell surface protein that is expressed on most epithelial cells
      • Cytokeratins: A family of intermediate filament proteins that are expressed in epithelial cells
    • Tumor-Specific Markers:
      • Markers that are specific for the type of cancer being studied
    • Markers to Exclude White Blood Cells:
      • CD45: A cell surface protein that is expressed on all leukocytes
  • Considerations:
    • CTCs can be difficult to distinguish from normal cells
    • The gating strategy must account for this and identify any cells that are epithelial, do not express CD45, and are also cancer specific
  • Triple positive cells will be confirmed as CTCs

Measurable (Minimal) Residual Disease (MRD)

  • Definition: The small number of cancer cells that remain in the body after treatment
  • Clinical Significance:
    • Prognosis: MRD status is a strong predictor of relapse
    • Therapeutic Monitoring: MRD monitoring can be used to guide treatment decisions
  • Methods for MRD Detection:
    • Flow Cytometry:
      • Principle: Uses flow cytometry to identify and quantify cancer cells based on their expression of specific markers
      • Advantages: Can detect MRD at very low levels
      • Disadvantages: Requires highly sensitive and specific antibodies
    • Polymerase Chain Reaction (PCR):
      • Principle: Uses PCR to amplify and detect cancer-specific DNA or RNA sequences
      • Advantages: Can detect MRD at even lower levels than flow cytometry
      • Disadvantages: Requires knowledge of cancer-specific DNA or RNA sequences
  • Markers Used for MRD Detection:
    • Leukemia-Associated Immunophenotypes (LAIPs):
      • Abnormal patterns of marker expression that are specific for the type of leukemia being studied
    • Aberrant Marker Expression:
      • Expression of markers that are not normally expressed on the cell type being studied
  • How to optimize:
    • The use of at least eight different markers allows for the identification of LAIPs and greatly increases sensitivity
    • In B-ALL, it has been shown to identify 1/10,000 events
  • Troubleshooting:
    • Lack of normal cells can mean the instrument is not sensitive enough
    • The samples must be acquired with at least 2 million cells to ensure accurate results

Circulating Endothelial Cells (CECs)

  • Definition: Cells that have detached from the lining of blood vessels and are circulating in the bloodstream
  • Clinical Significance:
    • Angiogenesis: CECs are involved in the formation of new blood vessels
    • Vascular Damage: Elevated levels of CECs can indicate damage to the blood vessels
    • Disease Monitoring: CEC counts can be used to monitor the progression of diseases that affect the blood vessels
  • Methods for CEC Detection:
    • Enrichment:
      • Immunomagnetic Enrichment: Uses antibodies against endothelial cell markers to capture CECs from the sample
    • Detection:
      • Immunofluorescence Staining: Uses fluorescent antibodies to identify CECs based on their expression of specific markers (e.g., CD31, CD146, von Willebrand factor (vWF))
      • Flow Cytometry: Uses flow cytometry to quantify the number of CECs in the sample
  • Markers Used for CEC Detection:
    • Endothelial Cell Markers:
      • CD31 (PECAM-1): A cell surface protein that is expressed on endothelial cells and platelets
      • CD146 (MCAM): A cell surface protein that is expressed on endothelial cells and some tumor cells
      • vWF: A protein that is involved in blood clotting and is stored in endothelial cells
    • Markers to Exclude White Blood Cells:
      • CD45: A cell surface protein that is expressed on all leukocytes
  • Common CEC markers:
    • CD45 (negative), CD31 (positive), CD146 (positive)
  • Limitations:
    • CECs can be difficult to distinguish from endothelial progenitor cells (EPCs)
    • The gating strategy must account for this
  • Considerations:
    • CECs are very rare, special techniques must be implemented to ensure accurate results
      • A large number of events should be required

General Strategies for Rare Event Analysis

  • Enrichment:
    • Use cell enrichment techniques to increase the frequency of the target cells
    • Immunomagnetic enrichment, microfluidic devices, and cell sorting can be used
  • High-Sensitivity Flow Cytometers:
    • Use flow cytometers with high sensitivity and low background noise
    • Optimize instrument settings to maximize signal intensity
  • Large Sample Volumes:
    • Process large sample volumes to increase the number of target cells
    • Use specialized tubes and collection devices to maximize sample recovery
  • Optimized Staining Protocols:
    • Use high-quality antibodies and dyes
    • Optimize antibody concentrations and incubation times
    • Use appropriate blocking reagents to reduce non-specific binding
  • Gating Strategies:
    • Use a hierarchical gating strategy to accurately identify the target cells
    • Use appropriate controls to define gating boundaries and account for background noise
    • Use Boolean gating to combine multiple markers and improve specificity
  • Statistical Analysis:
    • Use statistical methods to estimate the true frequency of the target cells and to assess the significance of the results
    • Consider using Poisson statistics to account for the random distribution of rare events
  • Cell Acquisition Number:
    • Since a low number of events can skew the data, it is important to acquire as many events as possible

Troubleshooting Rare Event Analysis

  • No Events Detected:
    • Possible Causes:
      • Extremely low frequency of target cells
      • Sample loss
      • Technical error
    • Troubleshooting Steps:
      • Check reagents, redo staining, and assess instrument function
  • Gating Difficulties:
    • Possible Causes:
      • Lack of clear separation between target and non-target events
      • High background noise
    • Troubleshooting Steps:
      • Select new, more specific, markers or adjust concentrations and techniques to reduce background events
  • Spurious Results:
    • Possible Causes:
      • Technical artifacts, high background
    • Troubleshooting Steps:
      • Implement proper controls, and carefully re-evaluate data

Key Terms

  • Rare Event Analysis: The process of identifying and quantifying cell populations that occur at very low frequencies
  • Circulating Tumor Cells (CTCs): Cells that have shed from a primary tumor and are circulating in the bloodstream
  • Measurable (Minimal) Residual Disease (MRD): The small number of cancer cells that remain in the body after treatment
  • Circulating Endothelial Cells (CECs): Cells that have detached from the lining of blood vessels and are circulating in the bloodstream
  • Immunomagnetic Enrichment: A technique that uses antibodies against cell surface markers to capture target cells
  • Epithelial Cell Adhesion Molecule (EpCAM): A cell surface protein that is expressed on most epithelial cells
  • Leukemia-Associated Immunophenotype (LAIP): Abnormal patterns of marker expression that are specific for the type of leukemia being studied